Skip to main content
. Author manuscript; available in PMC: 2011 Nov 13.
Published in final edited form as: Antiviral Res. 2009 Apr 1;83(1):71–79. doi: 10.1016/j.antiviral.2009.03.005

Fig. 2.

Fig. 2

Anti-WNV activities of compounds 11 (A), 17 (B), 35 (C), 39 (D), and 42 (E). For each compound, chemical structure, MTT-based cytotoxicity, replicon-based efficacy, and viral titer reduction-based efficacy are presented, with EC50 and CC50 values indicated. Vero cells were used in all presented experiments. For the results of WNV infection, the percentage of viral titer after compound treatment is indicated on the top of each bar (with the viral titer from the mock-treated sample set as 100%). Average results from three to four independent experiments are presented; error bars represent the standard deviations.